DocCode - SEQ.TXT
`
`SCORE Placeholder Sheet for IFW Content
`
`Application Number: 16159282
`
`Document Date: 1011212018
`
`The presence of this form in the IFW record indicates that the following document type was received
`in electronic format on the date identified above. This content is stored in the SCORE database.
`
`Since this was an electronic submission, there is no physical artifact folder, no artifact folder is
`recorded in PALM, and no paper documents or physical media exist. The TIFF images in the IFW
`record were created from the original documents that are stored in SCORE .
`
`• Sequence Listing
`
`At the time of document entry (noted above):
`• USPTO employees may access SCORE content via eDAN using the Supplemental Content
`tab, or via the SCORE web page.
`• External customers may access SCORE content via PAIR using the Supplemental Content
`tab.
`
`Form Revision Date: August 26, 2013
`
`APOTEX V. REGENERON IPR2022-01524
` REGENERON EXHIBIT 2005 PAGE 001
`
`

`

`PRELIMINARY
`AMENDMENT
`Under CFR 1.115
`
`Address to:
`Mail Stop Patent Application
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`Sir:
`
`Electronically Filed
`Attorney Docket No.
`REGN-008CIPCON 4
`To Be Assigned
`Confirmation No.
`Y ANCOPOULOS, GEORGE D.
`First Named Inventor
`To Be Assigned
`Application Number
`Filing Date
`October 12, 2018
`To Be Assigned
`Group Art Unit
`To Be Assigned
`Examiner Name
`Title:
`"Use of a VEGF Antagonist to Treat Angiogenic
`Eve Disorders"
`
`Prior to the examination of the above-referenced application on the merits, please enter the
`amendments below.
`
`APOTEX V. REGENERON IPR2022-01524
` REGENERON EXHIBIT 2005 PAGE 002
`
`

`

`AMENDMENTS TO THE SPECIFICATION
`
`Atty Dkt. No.: REGN-008CIPCON4
`USSN: To Be Assigned
`
`Please amend paragraph [0001] on pagel of the specification to read as follows:
`
`[0001] This application is a continuation of U.S. Patent Application Serial No. 15/471,506, filed
`
`March 28, 2017 (now allowed) which is a continuation of U.S. Patent Application Serial No.
`
`14/972,560, filed December 17, 2015, now U.S. Patent No. 9,669,069 issued June 6, 2017 which is a
`
`continuation of U.S. Patent Application Serial No. 13/940,370 filed July 12, 2013, now U.S. Patent
`
`No. 9,254,338 issued February 9, 2016 which is a continuation-in-part of International Patent
`
`Application No. PCT/US2012/020855, filed on January 11, 2012, which claims the benefit of US
`
`Provisional Application Nos. 61/432,245, filed on January 13, 2011, 61/434,836, filed on January 21,
`
`2011, and 61/561,957, filed on November 21, 2011, the contents of which are hereby incorporated by
`
`reference in their entireties.
`
`2
`
`APOTEX V. REGENERON IPR2022-01524
` REGENERON EXHIBIT 2005 PAGE 003
`
`

`

`Atty Dkt. No.: REGN-008CIPCON4
`USSN: To Be Assigned
`
`AMENDMENTS TO THE CLAIMS
`
`1. - 20. (Canceled)
`
`21.
`
`(New) A method for treating an angiogenic eye disorder in a patient, said method
`
`comprising sequentially administering to the patient
`
`a single initial dose of a VEGF antagonist, followed by
`
`one or more secondary doses of the VEGF antagonist, followed by
`
`one or more tertiary doses of the VEGF antagonist;
`
`wherein each secondary dose is administered 4 weeks after the immediately preceding dose; and
`
`wherein each tertiary dose is administered on an as-needed/pro re nata (PRN) basis, based on
`
`visual and/or anatomical outcomes as assessed by a physician or other qualified medical professional;
`
`wherein the VEGF antagonist is a receptor-based chimeric molecule comprising an
`
`immunoglobin-like (lg) domain 2 of a first VEGF receptor and lg domain 3 of a second VEGF receptor,
`
`and a multimerizing component.
`
`22.
`
`(New) The method of claim 21, wherein the VEGF antagonist is aflibercept.
`
`23.
`
`(New) The method of claim 22, wherein all doses of the VEGF antagonist are
`
`administered to the patient by intraocular administration.
`
`24.
`
`(New) The method of claim 23, wherein the intraocular administration is intravitreal
`
`administration.
`
`25.
`
`(New) The method of claim 24, wherein all doses of the VEGF antagonist comprise from
`
`about 0.5 mg to about 2 mg of the VEGF antagonist.
`
`26.
`
`(New) The method of claim 25, wherein all doses of the VEGF antagonist comprise 0.5
`
`mg of the VEGF antagonist.
`
`3
`
`APOTEX V. REGENERON IPR2022-01524
` REGENERON EXHIBIT 2005 PAGE 004
`
`

`

`27.
`
`(New) The method of claim 25, wherein all doses of the VEGF antagonist comprise 2 mg
`
`of the VEGF antagonist.
`
`Atty Dkt. No.: REGN-008CIPCON4
`USSN: To Be Assigned
`
`28.
`
`(New) The method of claim 27, wherein the angiogenic eye disorder is selected from the
`
`group consisting of: age related macular degeneration, diabetic retinopathy, diabetic macular edema,
`
`central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
`
`29.
`
`(New) The method of claim 28 wherein the angiogenic eye disorder is age related
`
`macular degeneration.
`
`30.
`
`(New) The method of claim 28 wherein the angiogenic eye disorder is diabetic
`
`retinopathy.
`
`31.
`
`(New) The method of claim 28, wherein the angiogenic eye disorder is diabetic macular
`
`edema.
`
`32.
`
`(New) A method for treating an angiogenic eye disorder in a patient, said method
`
`comprising sequentially administering to the patient
`
`a single initial dose of a VEGF antagonist, followed by
`
`one or more secondary doses of the VEGF antagonist, followed by
`
`one or more tertiary doses of the VEGF antagonist;
`
`wherein each secondary dose is administered 4 weeks after the immediately preceding dose; and
`
`wherein each tertiary dose is administered 12 weeks after the immediately preceding dose;
`
`wherein the VEGF antagonist is a receptor-based chimeric molecule comprising
`
`an immunoglobin-like (lg) domain 2 of a first VEGF receptor and lg domain 3 of a second
`
`VEGF receptor, and a multimerizing component.
`
`33.
`
`(New) The method of claim 22, wherein the VEGF antagonist is aflibercept.
`
`34.
`
`(New) The method of claim 23, wherein all doses of the VEGF antagonist are
`
`administered to the patient by intraocular administration.
`
`4
`
`APOTEX V. REGENERON IPR2022-01524
` REGENERON EXHIBIT 2005 PAGE 005
`
`

`

`Atty Dkt. No.: REGN-008CIPCON4
`USSN: To Be Assigned
`
`35.
`
`(New) The method of claim 24, wherein the intraocular administration is intravitreal
`
`administration.
`
`36.
`
`(New) The method of claim 25, wherein all doses of the VEGF antagonist comprise from
`
`about 0.5 mg to about 2 mg of the VEGF antagonist.
`
`37.
`
`(New) The method of claim 36, wherein all doses of the VEGF antagonist comprise 0.5
`
`mg of the VEGF antagonist.
`
`38.
`
`(New) The method of claim 36, wherein all doses of the VEGF antagonist comprise 2 mg
`
`of the VEGF antagonist.
`
`39.
`
`(New) The method of claim 38, wherein the angiogenic eye disorder is selected from the
`
`group consisting of: age related macular degeneration, diabetic retinopathy, diabetic macular edema,
`
`central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
`
`40.
`
`(New) The method of claim 39 wherein the angiogenic eye disorder is age related
`
`macular degeneration.
`
`41.
`
`(New) The method of claim 39 wherein the angiogenic eye disorder is diabetic
`
`retinopathy.
`
`42.
`
`(New) The method of claim 39, wherein the angiogenic eye disorder is diabetic macular
`
`edema.
`
`5
`
`APOTEX V. REGENERON IPR2022-01524
` REGENERON EXHIBIT 2005 PAGE 006
`
`

`

`Atty Dkt. No.: REGN-008CIPCON4
`USSN: To Be Assigned
`
`REMARKS UNDER 37 CFR § 1.115
`
`Formal Matters
`
`Claims 21-42 are pending after entry of the amendments set forth herein.
`
`Claims 1-20 are canceled without prejudice.
`
`Claims 21-42 are added.
`
`Support for new claims 21-42 can be found in originally pending now canceled claims 1-20, and
`
`throughout the specification.
`
`The specification has been amended to update the cross-reference to related application section.
`
`No new matter has been added.
`
`PARENT APPLICATION
`
`The parent application has been allowed. Further, as indicated above, correspondence and
`
`support for the current claims relative to those of the parent application can be reviewed and confirmed.
`
`In the event the Examiner has any questions with respect to claim support or other issues in connection
`
`with the application, the Examiner is respectfully requested to contact the undersigned attorney at the
`
`indicated telephone number to arrange for an interview to expedite this position of this application.
`
`STATEMENT UNDER 37 C.F.R. §§1.56 AND 1.2
`
`Applicants hereby advise the Examiner of the status of a co-pending application in compliance
`
`with the Applicant's duty to disclose under 37 C.F.R. §§1.56 and 1.2 ( see also MPEP §2001.06(b)) as
`
`discussed in McKesson Info. Soln. Inc., v. Bridge Medical Inc., 487 F.3d 897; 82 USPQ2d 1865 (Fed.
`
`Cir. 2007).
`
`The Applicants wish to bring to the Examiner's attention U.S. Patent Application No.
`
`13/940,370, filed July 12, 2013 which issued on February 9, 2016 as U.S. Patent 9,254,338.
`
`The Applicants wish to bring to the Examiner's attention U.S. Patent Application No.
`
`14/972,560, filed December 17, 2015 which issued on June 6, 2018 as U.S. Patent No. 9,669,069.
`
`The Applicants wish to bring to the Examiner's attention that a Notice of Allowance was mailed
`
`on July 26, 2018 in co-pending U.S. Patent Application No. 15/471,506, filed March 28, 2017.
`
`6
`
`APOTEX V. REGENERON IPR2022-01524
` REGENERON EXHIBIT 2005 PAGE 007
`
`

`

`The Applicants wish to bring to the Examiner's attention co-pending U.S. Patent Application No.
`
`16/055,847, filed August 6, 2018.
`
`Atty Dkt. No.: REGN-008CIPCON4
`USSN: To Be Assigned
`
`These documents are available on PAIR, and thus are not provided with this
`
`communication. Please inform the undersigned if there is any difficulty in obtaining the documents
`
`from PAIR.
`
`CONCLUSION
`
`Applicant submits that all of the claims are in condition for allowance, which action is requested.
`
`If the Examiner finds that a telephone conference would expedite the prosecution of this application,
`
`please telephone the undersigned at the number provided.
`
`The Commissioner is hereby authorized to charge any underpayment of fees up to a strict limit of
`
`$3,000.00 beyond that authorized on the credit card, but not more than $3,000.00 in additional fees due
`
`with any communication for the above referenced patent application, including but not limited to any
`
`necessary fees for extensions of time, or credit any overpayment of any amount to Deposit Account No.
`
`50-0815, order number REGN-008CIPCON4.
`
`Respectfully submitted,
`BOZICEVIC, FIELD & FRANCIS LLP
`
`By: --'-/=K=ar=l'-""BC....oc..cz=ic~e'""'v""'"ic""",'"""R"""e"""g"'". ""'"N"'"'o'""'."""2'"""8""",8"""'0'""'7-'-/_
`Karl Bozicevic
`Registration No. 28,807
`
`Date:
`
`- - - - -= . c~ . . . . c . . . . c . .~~~ - " ' - - - -
`
`12 October 2018
`
`Bozicevic, Field & Francis LLP
`201 Redwood Shores Parkway, Suite 200
`Redwood City, California 94065
`Telephone: (650) 327-3400
`Direct: (650) 833-7735
`Facsimile: (650) 327-3231
`
`7
`
`APOTEX V. REGENERON IPR2022-01524
` REGENERON EXHIBIT 2005 PAGE 008
`
`

`

`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`
`PTO/AIA/14
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`REGN-008CIPCON4
`
`Application Number
`
`Title of Invention
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the
`bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.
`This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document
`may be printed and included in a paper filed application.
`
`Secrecy Order 37 CFR 5.2:
`D Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37
`
`CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)
`
`Inventor Information:
`
`Inventor
`Legal Name
`
`1
`
`Prefix Given Name
`
`Middle Name
`
`Family Name
`
`Suffix
`
`D.
`George
`Residence Information (Select One) @ US Residency
`I State/Province
`City
`Yorktown Heights
`
`YANCOPOULOS
`0 Active US Military Service
`0 Non US Residency
`I us
`I Country of Residence i
`I NY
`
`Mailing Address of Inventor:
`
`Address 1
`
`Address2
`
`c/o Regeneron Pharmaceuticals, Inc.
`
`777 Old Saw Mill River Road
`
`City
`
`I Tarrytown
`Postal Code
`
`I State/Province
`I , os91
`I us
`I Country i
`All Inventors Must Be Listed - Additional Inventor Information blocks may be generated
`within this form by selecting the Add button.
`
`I NY
`
`I Add
`
`I
`
`Correspondence Information:
`Enter either Customer Number or complete the Correspondence Information section below.
`For further information see 37 CFR 1.33(a).
`D An Address is being provided for the correspondence Information of this application.
`Customer Number
`
`96387
`
`Email Address
`
`docket@bozpat.com
`
`Application Information:
`
`I
`
`I Add Email
`
`I
`
`I Remove Email I
`
`Title of the Invention
`
`Attorney Docket Number
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`I Small Entity Status Claimed D
`
`REGN-008CIPCON4
`
`Application Type
`
`Subject Matter
`
`Total Number of Drawing Sheets (if any)
`
`I ,
`
`I Suggested Figure for Publication (if any)
`
`I ,
`
`WEBADS 1.0
`
`APOTEX V. REGENERON IPR2022-01524
` REGENERON EXHIBIT 2005 PAGE 009
`
`

`

`PTO/AIA/14 (08-15)
`Approved for use through 04/30/2017. 0MB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`REGN-008CIPCON4
`
`Application Number
`
`Title of Invention
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`Filing By Reference:
`Only complete this section when filing an application by reference under 35 U.S.C. 111 (c) and 37 CFR 1.57(a). Do not complete this section if
`application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be
`provided in the appropriate section(s) below (i.e., "Domestic Benefit/National Stage Information" and "Foreign Priority Information").
`
`For the purposes of a filing date under 37 CFR 1.53(b), the description and any drawings of the present application are replaced by this
`reference to the previously filed application, subject to conditions and requirements of 37 CFR 1.57(a).
`
`Application number of the previously
`filed application
`
`Filing date (YYYY-MM-DD)
`
`i-
`Intellectual Property Authority or Country
`
`Publication Information:
`D Request Early Publication (Fee required at time ofRequest 37 CFR 1.219)
`35 u.s.c.
`Request Not to Publish. I hereby request that the attached application not be published under
`D 122(b) and certify that the invention disclosed in the attached application has not and will not be the subject of an
`application filed in another country, or under a multilateral international agreement, that requires publication at eighteen
`months after filing.
`
`Representative Information:
`
`..
`Representative information should be provided for all
`pract1t1oners having a power of attorney in the application. Providing
`this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32).
`Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer Number
`will be used for the Representative Information during processing.
`
`Please Select One:
`
`@ Customer Number
`
`Customer Number
`
`96387
`
`I O US Patent Practitioner 10 Limited Recognition (37 CFR 11.9)
`
`Prefix
`
`Given Name
`
`Middle Name
`
`Family Name
`
`Suffix
`
`Registration Number
`
`Prefix
`
`Given Name
`
`Middle Name
`
`Family Name
`
`Suffix
`
`I Remove I
`
`I Remove I
`
`Registration Number
`
`Additional Representative Information blocks may be generated within this form by
`selecting the Add button.
`
`WEB ADS 1.0
`
`APOTEX V. REGENERON IPR2022-01524
` REGENERON EXHIBIT 2005 PAGE 010
`
`

`

`PTO/AIA/14 (08-15)
`Approved for use through 04/30/2017. 0MB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`REGN-008CIPCON4
`
`Application Number
`
`Title of Invention
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`Domestic Benefit/National Stage Information:
`This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e}, 120, 121, 365(c}, or 386(c) or indicate National
`Stage entry from a PCT application. Providing benefit claim information in the Application Data Sheet constitutes the specific
`reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
`When referring to the current application, please leave the "Application Number" field blank.
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Filing or 371 (c) Date
`(YYYY-MM-DD)
`
`Continuation of
`
`15471506
`
`2017-03-28
`
`Application
`Number
`
`Continuity Type
`
`Prior Application
`Number
`
`Filing Date
`(YYYY-MM-DD)
`
`Patent Number
`
`15471506
`
`Continuation of
`
`14972560
`
`2015-12-17
`
`9669069
`
`Application
`Number
`
`Continuity Type
`
`Prior Application
`Number
`
`Filing Date
`(YYYY-MM-DD)
`
`Patent Number
`
`14972560
`
`Continuation of
`
`13940370
`
`2013-07-12
`
`9254338
`
`Issue Date
`(YYYY-MM-DD)
`
`2017-06-06
`
`Issue Date
`(YYYY-MM-DD)
`
`2016-02-09
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Fi ing or 371 (c) Date
`(YYYY-MM-DD)
`
`13940370
`
`Continuation in part of
`
`PCT/US2012/020855
`
`2012-01-11
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Fi ing or 371 (c) Date
`(YYYY-MM-DD)
`
`PCT /US2012/020855
`
`Claims benefit of provisional
`
`61432245
`
`2011-01-13
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Fi ing or 371 (c) Date
`(YYYY-MM-DD)
`
`PCT /US2012/020855
`
`Claims benefit of provisional
`
`61434836
`
`2011-01-21
`
`WEB ADS 1.0
`
`APOTEX V. REGENERON IPR2022-01524
` REGENERON EXHIBIT 2005 PAGE 011
`
`

`

`PTO/AIA/14 (08-15)
`Approved for use through 04/30/2017. 0MB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`REGN-008CIPCON4
`
`Application Number
`
`Title of Invention
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Fi ing or 371 (c) Date
`(YYYY-MM-DD)
`
`PCT /US2012/020855
`
`Claims benefit of provisional
`
`61561957
`
`2011-11-21
`
`Additional Domestic Benefit/National Stage Data may be generated within this form by
`selecting the Add button.
`
`Foreign Priority Information:
`
`This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet
`constitutes the claim for priority as required by 35U.S.C.119(b) and 37 CFR 1 .55. When priority is claimed to a foreign application that is eligible
`for retrieval under the priority document exchange program (POX) the information J,ill be used by the Office to automatically attempt retrieval
`pursuant to 37 CFR 1 .55(i)(l) and (2). Under the PDX program, applicant bears the ultimate responsibility for ensuring that a copy of the foreign
`application is received by the Office from the participating foreign intellectual property office, or a certified copy of the foreign priority
`application is filed, within the time period specified in 37 CFR 1.55(g)(l).
`
`Application Number
`
`Country 1
`
`Filing Date (YYYY-MM-DD)
`
`Access Codei(if applicable)
`
`us
`Additional Foreign Priority Data may be generated within this form by selecting the Add
`button.
`
`Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition
`Applications
`
`This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also
`contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March
`D 16,20n.
`NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March
`16, 2013, will be examined under the first inventor to file provisions of the AIA.
`
`WEBADS 1.0
`
`APOTEX V. REGENERON IPR2022-01524
` REGENERON EXHIBIT 2005 PAGE 012
`
`

`

`PTO/AIA/14 (08-15)
`Approved for use through 04/30/2017. 0MB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`REGN-008CIPCON4
`
`Application Number
`
`Title of Invention
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`Authorization or Opt-Out of Authorization to Permit Access:
`
`When this Application Data Sheet is properly signed and filed with the application, applicant has provided written authority to
`permit a participating foreign intellectual property (IP) office access to the instant application-as-filed (see paragraph A in
`subsection 1 below) and the European Patent Office (EPO) access to any search results from the instant application (see
`paragraph Bin subsection 1 below).
`
`Should applicant choose not to provide an authorization identified in subsection 1 below, applicant must opt-out of the
`authorization by checking the corresponding box A or B or both in subsection 2 below.
`
`NOTE: This section of the Application Data Sheet is ONLY reviewed and processed with the INITIAL filing of an application.
`After the initial filing of an application, an Application Data Sheet cannot be used to provide or rescind authorization for access
`by a foreign IP office(s). Instead, Form PTO/SB/39 or PTO/SB/69 must be used as appropriate.
`
`1. Authorization to Permit Access by a Foreign Intellectual Property Office(s)
`
`A. Priority Document Exchange (PDX) - Unless box A in subsection 2 (opt-out of authorization) is checked, the undersigned
`hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean
`Intellectual Property Office (KIPO), the State Intellectual Property Office of the People's Republic of China (SIPO), the World
`Intellectual Property Organization (WIPO), and any other foreign intellectual property office participating with the USPTO in a
`bilateral or multilateral priority document exchange agreement in which a foreign application claiming priority to the instant
`patent application is filed, access to: (1) the instant patent application-as-filed and its related bibliographic data, (2) any foreign
`or domestic application to which priority or benefit is claimed by the instant application and its related bibliographic data, and
`(3) the date offiling of this Authorization. See 37 CFR l.14(h)(l ).
`
`B. Search Results from U.S. Application to EPO- Unless box Bin subsection 2 (opt-out of authorization) is checked, the
`undersigned hereby grants the USPTO authority to provide the EPO access to the bibliographic data and search results from
`the instant patent application when a European patent application claiming priority to the instant patent application is filed. See
`37 CFR l.14(h)(2).
`
`The applicant is reminded that the EPO's Rule 141 (1) EPC (European Patent Convention) requires applicants to submit a copy of
`search results from the instant application without delay in a European patent application that claims priority to the instant
`application.
`
`2. Opt-Out of Authorizations to Permit Access by a Foreign Intellectual Property Office(s)
`
`A. Applicant DOES NOT authorize the USPTO to permit a participating foreign IP office access to the instant
`D application-as-filed. If this box is checked, the USPTO will not be providing a participating foreign IP office with any
`documents and information identified in subsection 1 A above.
`
`B. Applicant DOES NOT authorize the USPTO to transmit to the EPO any search results from the instant patent
`D application. If this box is checked, the USPTO will not be providing the EPO with search results from the instant application.
`
`NOTE: Once the application has published or is otherwise publicly available, the USPTO may provide access to the application in
`accordance with 37 CFR 1.14.
`
`WEB ADS 1.0
`
`APOTEX V. REGENERON IPR2022-01524
` REGENERON EXHIBIT 2005 PAGE 013
`
`

`

`PTO/AIA/14 (08-15)
`Approved for use through 04/30/2017. 0MB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`REGN-008CIPCON4
`
`Application Number
`
`Title of Invention
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`Applicant Information:
`
`Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have
`an assignment recorded by the Office.
`
`Applicant
`1
`If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed. The
`information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR 1.43; or the
`name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person who otherwise shows
`sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an applicant under 37 CFR 1.46 (assignee,
`person to whom the inventor is obligated to assign, or person who otherwise shows sufficient proprietary interest) together with one or more
`joint inventors, then the joint inventor or inventors who are also the applicant should be identified in this section.
`
`0 Assignee
`@ Person to whom the inventor is obligated to assign.
`If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:
`
`Person who shows sufficient proprietary interest
`
`lo Legal Representative under 35 U.S.C. 117
`lo
`
`I Clear
`
`I
`
`lo Joint Inventor
`
`Name of the Deceased or Legally Incapacitated Inventor:
`
`I
`
`If the Applicant is an Organization check here.
`
`~
`
`Organization Name
`
`I REGENERON PHARMACEUTICALS, INC.
`
`Mailing Address Information For Applicant:
`
`777 Old Saw Mill River Road
`
`Tarrytown
`
`Address 1
`
`Address 2
`
`City
`Country 1 I us
`Phone Number
`
`Email Address
`
`I
`
`State/Province
`
`Postal Code
`
`Fax Number
`
`NY
`
`10591
`
`Additional Applicant Data may be generated within this form by selecting the Add button.
`
`WEBADS 1.0
`
`APOTEX V. REGENERON IPR2022-01524
` REGENERON EXHIBIT 2005 PAGE 014
`
`

`

`PTO/AIA/14 (08-15)
`Approved for use through 04/30/2017. 0MB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`REGN-008CIPCON4
`
`Application Number
`
`Title of Invention
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`Assignee Information including Non-Applicant Assignee Information:
`
`Providing assignment information in this section does not substitute for compliance with any requirement of part 3 ofTitle 37 of
`CFR to have an assignment recorded by the Office.
`
`1
`Assignee
`Complete this section if assignee information, including non-applicant assignee information, is desired to be included on the patent application
`publication. An assignee-applicant identified in the "Applicant Information" section will appear on the patent application publication as an
`applicant. For an assignee-applicant, complete this section only if identification as an assignee is also desired on the patent application
`publication.
`
`If the Assignee or Non-Applicant Assignee is an Organization check here.
`
`~
`
`Organization Name
`
`I REGEN ERON PHARMACEUTICALS, INC.
`
`Mailing Address Information For Assignee including Non-Applicant Assignee:
`
`777 Old Saw Mill River Road
`
`I Tarrytown
`
`Address 1
`
`Address 2
`
`City
`
`Country i
`
`I us
`
`Phone Number
`
`Email Address
`
`State/Province
`
`Postal Code
`
`Fax Number
`
`NY
`
`10591
`
`Additional Assignee or Non-Applicant Assignee Data may be generated within this form by
`selecting the Add button.
`
`WEBADS 1.0
`
`APOTEX V. REGENERON IPR2022-01524
` REGENERON EXHIBIT 2005 PAGE 015
`
`

`

`PTO/AIA/14 (08-15)
`Approved for use through 04/30/2017. 0MB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`REGN-008CIPCON4
`
`Application Number
`
`Title of Invention
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`Signature:
`NOTE: This Application Data Sheet must be signed in accordance with 37 CFR 1.33(b). However, if this Application Data Sheet
`is submitted with the INITIAL filing of the application and either box A or B is not checked in subsection 2 of the
`"Authorization or Opt-Out of Authorization to Permit Access" section, then this form must also be signed in accordance
`with 37 CFR 1.14(c).
`This Application Data Sheet must be signed by a patent practitioner if one or more of the applicants is a juristic entity (e.
`g., corporation or association). If the applicant is two or more joint inventors, this form must be signed by a patent practitioner,
`all joint inventors who are the applicant, or one or more joint inventor-applicants who have been given power of attorney (e.g.,
`see USPTO Form PTO/AIA/81) on behalfofalljoint inventor-applicants.
`See 37 CFR 1.4(d) for the manner of making signatures and certifications.
`
`Signature
`
`/Karl Boziceivd
`
`Date (YYYY-MM-DD)
`
`28807
`
`I Registration Number
`Additional Signature may be generated within this form by selecting the Add button.
`
`I Last Name
`
`I Bozicevic
`
`First Name
`
`Karl
`
`WEB ADS 1.0
`
`APOTEX V. REGENERON IPR2022-01524
` REGENERON EXHIBIT 2005 PAGE 016
`
`

`

`Electronic Patent Application Fee Transmittal
`
`Application Number:
`
`Filing Date:
`
`Title of Invention:
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`First Named Inventor/Applicant Name:
`
`George D. YANCOPOULOS
`
`Filer:
`
`Attorney Docket Number:
`
`Filed as Large Entity
`
`Filing Fees for Utility under 35 USC 111 (a)
`
`Karl Bozicevic
`
`REGN-008CIPCON4
`
`Description
`
`Fee Code
`
`Quantity
`
`Amount
`
`Sub-Total in
`USO($)
`
`UTILITY APPLICATION FILING
`
`UTILITY SEARCH FEE
`
`UTILITY EXAMINATION FEE
`
`1011
`
`1111
`
`1311
`
`1
`
`1
`
`1
`
`300
`
`660
`
`760
`
`300
`
`660
`
`760
`
`Basic Filing:
`
`Pages:
`
`Claims:
`
`CLAIMS IN EXCESS OF 20
`
`1202
`
`2
`
`100
`
`200
`
`Miscellaneous-Filing:
`
`Petition:
`
`APOTEX V. REGENERON IPR2022-01524
` REGENERON EXHIBIT 2005 PAGE 017
`
`

`

`Description
`
`Fee Code
`
`Quantity
`
`Amount
`
`Sub-Total in
`USO($)
`
`Patent-Appeals-and-Interference:
`
`Post-Allowance-and-Post-Issuance:
`
`Extension-of-Time:
`
`Miscellaneous:
`
`Total in USO($)
`
`1920
`
`APOTEX V. REGENERON IPR2022-01524
` REGENERON EXHIBIT 2005 PAGE 018
`
`

`

`Electronic Acknowledgement Receipt
`
`EFSID:
`
`Application Number:
`
`33999315
`
`16159282
`
`International Application Number:
`
`Confirmation Number:
`
`8618
`
`Title of Invention:
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`First Named Inventor/Applicant Name:
`
`George D. YANCOPOULOS
`
`Customer Number:
`
`96387
`
`Filer:
`
`Karl Bozicevic
`
`Filer Authorized By:
`
`Attorney Docket Number:
`
`REGN-008CIPCON4
`
`Receipt Date:
`
`12-0CT-2018
`
`Filing Date:
`
`Time Stamp:
`
`17:13:28
`
`Application Type:
`
`Utility under 35 USC 111 (a)
`
`Payment information:
`
`Submitted with Payment
`
`Payment Type
`
`Payment was successfully received in RAM
`
`yes
`
`CARD
`
`$1920
`
`RAM confirmation Number
`
`1015181NTEFSW17141600
`
`Deposit Account
`
`Authoriz